William Blair analyst Raju Prasad maintained a Hold rating on Bluebird Bio (BLUE – Research Report) on June 12. The company's shares closed last Thursday at $3.06, close to its 52-week low of $2.87. According to TipRanks.com, Prasad has 0 stars on 0-5 stars ranking scale with an average return of -8.6% and a 36.3% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Rocket Pharmaceuticals, and Crispr Therapeutics AG. The word on The Street in general, suggests a Moderate Sell analyst consensus rating for Bluebird Bio with a $2.67 average price target, which is a -19.8% downside from current levels.
https://www.tipranks.com/news/blurbs/william-blair-maintains-a-hold-rating-on-bluebird-bio-blue?utm_source=advfn.com&utm_medium=referral
bluebird bio (NASDAQ:BLUE)
Historical Stock Chart
From Nov 2022 to Dec 2022 Click Here for more bluebird bio Charts.
bluebird bio (NASDAQ:BLUE)
Historical Stock Chart
From Dec 2021 to Dec 2022 Click Here for more bluebird bio Charts.